论文部分内容阅读
目的探讨卡维地洛治疗充血性心力衰竭的临床疗效。方法将2008年1月—2010年6月我院慢性充血性心力衰竭患者92例随机分为治疗组和对照组各46例,2组在常规抗心力衰竭药物治疗下,治疗组加用卡维地洛,起始剂量2.5m g,每日2次,每1周～2周加倍,直至患者不能耐受或达靶剂量30m g/d.根据治疗前后症状、体征及超声心动图判断疗效。结果卡维地洛组治疗总有效率(91.30%)高于对照组(70.09%),差异有统计学意义(P<0.05);卡维地洛组左室射血分数(LVFF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVED D)改善优于对照组(P<0.05)。结论卡维地洛治疗充血性心力衰竭疗效确切。
Objective To investigate the clinical efficacy of carvedilol in the treatment of congestive heart failure. Methods From January 2008 to June 2010, 92 patients with chronic congestive heart failure in our hospital were randomly divided into treatment group (46 cases) and control group (46 cases). In the two groups, with conventional anti-heart failure drug treatment, Dexterol, the initial dose of 2.5mg, 2 times a day, every 1 week to 2 weeks to double until the patient can not tolerate or reach the target dose of 30m g / d, according to the symptoms and signs before and after treatment to determine the efficacy and echocardiography. Results The total effective rate of carvedilol group (91.30%) was higher than that of the control group (70.09%), the difference was statistically significant (P <0.05); the carvedilol group left ventricular ejection fraction (LVFF) LVESD and LVEDD improved better than the control group (P <0.05). Conclusion Carvedilol is effective in treating congestive heart failure.